SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
56S1.DE Key Statistics, Chart & Performance
The current stock price of 56S1.DE is 207.7 EUR. In the past month the price increased by 8.67%. In the past year, price increased by 18.86%.
56S1.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 48.12 | 20.19B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 54.28 | 18.53B | ||
| SRT.DE | SARTORIUS AG | 42.28 | 14.44B | ||
| QIA.DE | QIAGEN N.V. | 18.92 | 8.37B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 15.57 | 2.27B | ||
| EVT.DE | EVOTEC SE | N/A | 1.86B | ||
| GXI.DE | GERRESHEIMER AG | 7.13 | 908.40M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.83 | 212.66M | ||
| MLC.I | MALIN CORP PLC | N/A | 33.34M |
Related stock screener links
About 56S1.DE
Company Profile
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Company Info
SARTORIUS STEDIM BIOTECH
Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex
Aubagne PACA FR
Employees: 9961
Phone: 33442845600
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What does SARTORIUS STEDIM BIOTECH do?
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
What is the stock price of SARTORIUS STEDIM BIOTECH today?
The current stock price of 56S1.DE is 207.7 EUR. The price decreased by -1.8% in the last trading session.
What is the dividend status of SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a dividend yield of 0.32%. The yearly dividend amount is currently 0.71.
How is the ChartMill rating for SARTORIUS STEDIM BIOTECH?
56S1.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does SARTORIUS STEDIM BIOTECH belong to?
SARTORIUS STEDIM BIOTECH (56S1.DE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
Can you provide the PE ratio for 56S1 stock?
The PE ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 48.19. This is based on the reported non-GAAP earnings per share of 4.31 and the current share price of 207.7 EUR.
Can you provide the growth outlook for SARTORIUS STEDIM BIOTECH?
The Revenue of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 9.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
56S1.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 56S1.DE. When comparing the yearly performance of all stocks, 56S1.DE is one of the better performing stocks in the market, outperforming 87.87% of all stocks.
56S1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE. Both the profitability and the financial health of 56S1.DE get a neutral evaluation. Nothing too spectacular is happening here.
56S1.DE Financial Highlights
Over the last trailing twelve months 56S1.DE reported a non-GAAP Earnings per Share(EPS) of 4.31. The EPS increased by 35.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.96% | ||
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| Debt/Equity | 0.5 |
56S1.DE Forecast & Estimates
18 analysts have analysed 56S1.DE and the average price target is 240.69 EUR. This implies a price increase of 15.88% is expected in the next year compared to the current price of 207.7.
For the next year, analysts expect an EPS growth of 29.41% and a revenue growth 9.03% for 56S1.DE